HIV Alert: Emerging Updates on Dual Therapy

Listen to downloadable audio from a series of live Webinars by Joseph J. Eron, Jr., MD, and Babafemi Taiwo, MBBS, in which the use of a recently approved dual-therapy regimen and data surrounding investigational 2-drug regimens are discussed and audience questions on these subjects are addressed.
Format: Audio (.mp3)
File Size: 8.35 MB
Released: January 18, 2018

Listen to downloadable audio from a series of live Webinars by Joseph J. Eron, Jr., MD, and Babafemi Taiwo, MBBS, in which the use of a recently approved dual-therapy regimen and data surrounding investigational 2-drug regimens are discussed and audience questions on these subjects are addressed. (~45 minutes)

Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from EMD Serono, Gilead Sciences, Janssen, Merck, Trio Health, and ViiV and funds for research support (to the University of North Carolina) from Gilead Sciences, Janssen, and ViiV.

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, and ViiV and funds for research support from ViiV.

Acknowledgements

Educational grant provided by:
ViiV Healthcare

Related Content

Downloadable slideset from Clinical Care Options on key aspects of HIV pharmacy service provision, with insights from Jennifer Cocohoba, PharmD

Jennifer Cocohoba Headshot Jennifer Cocohoba, PharmD Released: January 31, 2019

Downloadable slideset from Clinical Care Options on with expert insight on emerging ART strategies, including rapid ART initiation and dual therapy.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Eric S. Daar, MD
Released: January 30, 2019

Find out what pharmacists can do to expand and improve HIV service provision in this interactive CME/CPE module from Clinical Care Options

John Faragon, PharmD, BCPS, AAHIVP
Program Director
Jennifer Cocohoba Headshot Jennifer Cocohoba, PharmD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Pharmacists: 1.0 contact hour (0.1 CEUs) Released: January 30, 2019 Expiration: January 29, 2020

Commentary from David A. Wohl, MD, on latest HIV conference data behind virologically suppressed patients switching to new 2- and 3-drug combinations.

David A. Wohl, MD Released: January 23, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?